All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

sodium polystyrene sulfonate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	4487	25704-18-1

Description:

Molecule

Description

Synonyms: kayexalate sodium polystyrene sulfonate sodium p-styrenesulfonate homopolymer

A potassium ion exchange resin composed of benzene-diethyl polymer with ethenyl-benzene, sulfonated, sodium salt. Administered as an oral suspension, sodium polystyrene sulfonate lowers serum potassium levels by exchanging its sodium ions for potassium ions. Acting primarily in the large intestine, this agent also exchanges its sodium ions for calcium and magnesium ions, resulting in a decrease in serum calcium and magnesium levels. Molecular weight: Formula: (C8H7NaO3S)n CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Drug dosage:

Dose	Unit	Route
45	g	O

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
June 5, 1958	FDA	CONCORDIA PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperkalaemia	137.28	24.51	63	3788	64901	90559695
Hypokalaemia	134.11	24.51	78	3773	131038	90493558
Acute kidney injury	130.46	24.51	108	3743	320279	90304317
Arteriovenous fistula occlusion	81.09	24.51	14	3837	357	90624239
Blue toe syndrome	77.31	24.51	14	3837	472	90624124
Urinary retention	65.51	24.51	32	3819	37712	90586884
Facial nerve disorder	61.80	24.51	12	3839	593	90624003
Metabolic alkalosis	58.81	24.51	16	3835	3533	90621063
Crystal deposit intestine	51.08	24.51	8	3843	109	90624487
Head injury	49.83	24.51	25	3826	31163	90593433
Pneumonia aspiration	46.13	24.51	26	3825	40914	90583682
Renal impairment	43.63	24.51	36	3815	105385	90519211
Renal pain	42.62	24.51	15	3836	7744	90616852
Anaemia	41.30	24.51	62	3789	352740	90271856
Blood potassium increased	40.26	24.51	19	3832	20730	90603866
Eosinophilia	40.15	24.51	21	3830	28512	90596084
Granulomatous liver disease	39.72	24.51	9	3842	940	90623656
Lactic acidosis	38.61	24.51	25	3826	50438	90574158
Left ventricular hypertrophy	38.09	24.51	13	3838	6131	90618465
Cardiac failure	36.41	24.51	33	3818	109463	90515133
Ischaemic stroke	36.08	24.51	18	3833	22148	90602448
Drug interaction	35.83	24.51	51	3800	276402	90348194
Muscle strain	35.81	24.51	14	3837	9673	90614923
Gastrointestinal necrosis	33.05	24.51	10	3841	3215	90621381
Hypocalcaemia	32.44	24.51	21	3830	42347	90582249
Drug reaction with eosinophilia and systemic symptoms	32.26	24.51	21	3830	42737	90581859
Fall	32	24.51	66	3785	481744	90142852
Constipation	30.97	24.51	48	3803	280347	90344249
Renal failure	27.88	24.51	31	3820	130976	90493620
Tumour lysis syndrome	27.27	24.51	12	3839	11140	90613456
Sickle cell anaemia	26.39	24.51	6	3845	636	90623960

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperkalaemia	170.98	18.99	116	5615	80342	42535262
Crystal deposit intestine	150.79	18.99	24	5707	99	42615505
Acute kidney injury	87.06	18.99	167	5564	367170	42248434
Renin increased	37.21	18.99	8	5723	202	42615402
Chronic kidney disease	32.88	18.99	36	5695	47205	42568399
Renal failure	32.14	18.99	64	5667	143662	42471942
Gastrointestinal necrosis	28.57	18.99	13	5718	4115	42611489
Hypocalcaemia	28.28	18.99	27	5704	30146	42585458
Large intestinal ulcer	27.87	18.99	11	5720	2452	42613152
Toxic skin eruption	27.17	18.99	19	5712	13711	42601893
Nephroangiosclerosis	26.60	18.99	6	5725	190	42615414
Hypoprothrombinaemia	25.93	18.99	7	5724	469	42615135
Large intestine perforation	25.69	18.99	16	5715	9520	42606084
Metabolic acidosis	25.33	18.99	33	5698	51825	42563779
Lip ulceration	24.75	18.99	8	5723	1002	42614602
Biopsy liver	24.47	18.99	6	5725	274	42615330
Aplasia pure red cell	24.45	18.99	14	5717	7152	42608452
Anaemia	23.69	18.99	87	5644	280191	42335413
Blood potassium increased	22.11	18.99	19	5712	18517	42597087
Pneumothorax spontaneous	21.96	18.99	7	5724	839	42614765
Biopsy rectum abnormal	21.67	18.99	3	5728	3	42615601
Ileal perforation	20.34	18.99	7	5724	1064	42614540
Eosinophilia	19.37	18.99	23	5708	32876	42582728

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperkalaemia	289.93	19.71	166	9200	135630	110444303
Acute kidney injury	200.87	19.71	257	9109	635173	109944760
Crystal deposit intestine	192.19	19.71	31	9335	243	110579690
Hypokalaemia	102.58	19.71	100	9266	182348	110397585
Arteriovenous fistula occlusion	71.71	19.71	15	9351	534	110579399
Renal failure	68.55	19.71	90	9276	226484	110353449
Anaemia	66.14	19.71	144	9222	546942	110032991
Hypocalcaemia	63.48	19.71	49	9317	65317	110514616
Gastrointestinal necrosis	62.95	19.71	23	9343	6617	110573316
Blue toe syndrome	62.81	19.71	14	9352	674	110579259
Metabolic alkalosis	59.12	19.71	21	9345	5574	110574359
Eosinophilia	57.51	19.71	44	9322	57892	110522041
Facial nerve disorder	50.47	19.71	12	9354	770	110579163
Blood potassium increased	48.64	19.71	32	9334	33217	110546716
Large intestine perforation	48.35	19.71	25	9341	16604	110563329
Cardiac failure	44.01	19.71	66	9300	187560	110392373
Large intestinal ulcer	43.87	19.71	17	9349	5744	110574189
Tumour lysis syndrome	41.10	19.71	28	9338	30773	110549160
Metabolic acidosis	40.48	19.71	46	9320	99698	110480235
Renal impairment	39.58	19.71	63	9303	188382	110391551
Thrombocytopenia	37.77	19.71	88	9278	348797	110231136
Renin increased	36.46	19.71	8	9358	358	110579575
Chronic kidney disease	35.84	19.71	38	9328	76253	110503680
Drug interaction	33.80	19.71	106	9260	500077	110079856
Aplasia pure red cell	32.53	19.71	16	9350	9562	110570371
Renal pain	32.16	19.71	16	9350	9801	110570132
Toxic epidermal necrolysis	31.64	19.71	31	9335	56696	110523237
Urinary retention	31.48	19.71	34	9332	69649	110510284
Head injury	30.75	19.71	27	9339	42990	110536943
Biopsy rectum abnormal	30.74	19.71	4	9362	4	110579929
Intestinal ischaemia	29.74	19.71	18	9348	16161	110563772
Hepatitis cholestatic	28.38	19.71	18	9348	17548	110562385
Excessive granulation tissue	27.76	19.71	8	9358	1086	110578847
Pneumonia aspiration	27.24	19.71	34	9332	81199	110498734
Pain	26.69	19.71	25	9341	954930	109625003
Lactic acidosis	25.17	19.71	35	9331	92776	110487157
Left ventricular hypertrophy	25.03	19.71	15	9351	13229	110566704
Granulomatous liver disease	24.84	19.71	8	9358	1576	110578357
Bradycardia	24.76	19.71	46	9320	155471	110424462
Muscle strain	24.64	19.71	14	9352	11188	110568745
Nephroangiosclerosis	24.57	19.71	6	9360	431	110579502
Peritonitis	24.38	19.71	21	9345	32586	110547347
Hypoprothrombinaemia	24.28	19.71	7	9359	952	110578981
Lymphocele	23.54	19.71	8	9358	1863	110578070
Rhabdomyolysis	22.23	19.71	38	9328	120363	110459570
Infusion related reaction	22.20	19.71	3	9363	381159	110198774
Biopsy liver	22.18	19.71	6	9360	647	110579286
Hypoaldosteronism	22.03	19.71	6	9360	663	110579270
Hypothermia	21.85	19.71	18	9348	26284	110553649
Ileal perforation	21.67	19.71	7	9359	1393	110578540
Drug hypersensitivity	21.37	19.71	6	9360	454084	110125849
Toxic skin eruption	21.14	19.71	18	9348	27497	110552436
Rectal ulcer	21.06	19.71	8	9358	2559	110577374
Sickle cell anaemia	20.92	19.71	6	9360	801	110579132
Sepsis	20.82	19.71	68	9298	327278	110252655
Blood creatinine increased	20.71	19.71	47	9319	182842	110397091
Constipation	20.71	19.71	72	9294	357714	110222219
Multiple organ dysfunction syndrome	20.64	19.71	42	9324	151668	110428265
Lip ulceration	20.45	19.71	8	9358	2770	110577163
Headache	20.37	19.71	27	9339	882350	109697583
Ischaemic stroke	20.17	19.71	21	9345	41242	110538691
Pneumothorax spontaneous	19.88	19.71	7	9359	1810	110578123

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V03AE01	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Drugs for treatment of hyperkalemia and hyperphosphatemia
FDA MoA	N0000175357	Potassium Ion Exchange Activity
MeSH PA	D002411	Cation Exchange Resins
MeSH PA	D002614	Chelating Agents
MeSH PA	D007475	Ion Exchange Resins
MeSH PA	D064449	Sequestering Agents
FDA EPC	N0000178378	Potassium Binder

Related Drugs by ATC class:

V03AE Drugs for treatment of hyperkalemia and hyperphosphatemia 10 drugs

calcium acetatecalcium acetate and magnesium carbonatecalcium polystyrene sulfonatecolestilanferric citratelanthanum carbonatepatiromer calciumsevelamersodium zirconium cyclosilicatesucroferric oxyhydroxide

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hyperkalemia	indication	14140009
Hypocalcemia	contraindication	5291005
Bowel sounds absent	contraindication	16268000
Alkalosis	contraindication	21420006
Inflammatory bowel disease	contraindication	24526004	DOID:0050589
Hypovolemia	contraindication	28560003
Ischemic colitis	contraindication	30588004	DOID:0060181
Hypokalemia	contraindication	43339004
Fecal impaction	contraindication	44635007
Conduction disorder of the heart	contraindication	44808001
Chronic heart failure	contraindication	48447003
Gastrointestinal hemorrhage	contraindication	74474003
Intestinal obstruction	contraindication	81060008	DOID:8437
Chronic idiopathic constipation	contraindication	82934008
Kidney disease	contraindication	90708001	DOID:557
Prolonged QT interval	contraindication	111975006
Gastrointestinal obstruction	contraindication	126765001
Hypomagnesemia	contraindication	190855004
Edema	contraindication	267038008
Operation on gastrointestinal tract	contraindication	386621005
Gastrointestinal hypomotility	contraindication	421807004
Hypertensive urgency	contraindication	443482000
Colonic Necrosis	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D03263	KEGG_DRUG
4018241	VANDF
CHEBI:53279	CHEBI
CHEMBL1201484	ChEMBL_ID
C003321	MESH_SUPPLEMENTAL_RECORD_UI
1699G8679Z	UNII
DB01344	DRUGBANK_ID
1546437	RXNORM
1125	MMSL
1264	MMSL
5492	MMSL
d00743	MMSL
000753	NDDF
006664	NDDF
1002242008	SNOMEDCT_US
387149008	SNOMEDCT_US
710808009	SNOMEDCT_US
C0142915	UMLSCUI
C0137904	UMLSCUI
28210-41-5	SECONDARY_CAS_RN
58817179	PUBCHEM_CID
8324	INN_ID
ZSL2FB6GXN	UNII
CHEBI:53277	CHEBI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	10135-146	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	17 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	10702-036	POWDER	1 g	ORAL	ANDA	16 sections
SODIUM POLYSTYRENE SULFONATE	HUMAN PRESCRIPTION DRUG LABEL	1	11534-166	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	16 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0024	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	23 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0036	POWDER	1 g	ORAL	ANDA	14 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	17856-1136	POWDER	1 g	ORAL	ANDA	14 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	24658-760	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	23 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	35573-108	SUSPENSION	15 g	ORAL	ANDA	17 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	42806-013	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	23 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	46287-006	SUSPENSION	15 g	ORAL	ANDA	17 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	46287-012	POWDER, FOR SUSPENSION	1 g	ORAL	ANDA	24 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	55154-7353	SUSPENSION	15 g	ORAL	ANDA	17 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	55154-7353	SUSPENSION	15 g	ORAL	ANDA	17 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	62135-340	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	16 sections
SODIUM POLYSTYRENE SULFONATE	HUMAN PRESCRIPTION DRUG LABEL	1	62250-660	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	12 sections
Kionex	HUMAN PRESCRIPTION DRUG LABEL	1	62559-356	SUSPENSION	15 g	ORAL	ANDA	16 sections
Kionex	HUMAN PRESCRIPTION DRUG LABEL	1	62559-356	SUSPENSION	15 g	ORAL	ANDA	16 sections
SODIUM POLYSTYRENE SULFONATE	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2390	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	16 sections
SODIUM POLYSTYRENE SULFONATE	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8849	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	16 sections
SODIUM POLYSTYRENE SULFONATE	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8850	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	16 sections
Sodium Polystyrene Sulfonate	HUMAN PRESCRIPTION DRUG LABEL	1	70166-712	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	18 sections
SODIUM POLYSTYRENE SULFONATE	HUMAN PRESCRIPTION DRUG LABEL	1	71335-2855	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	16 sections
SODIUM POLYSTYRENE SULFONATE	HUMAN PRESCRIPTION DRUG LABEL	1	72162-1230	POWDER, FOR SUSPENSION	4.10 meq	ORAL	ANDA	16 sections